Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34893 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Xian-Yang Qin und 35 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Hepatocellular, Liver Neoplasms, N-Myc Proto-Oncogene Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Cell Science Research Foundation, The Jikei University, Tokyo Biochemical Research Foundation.
Abstract (Originalsprache)
The proto‐oncogene MYCN expression marked a cancer stem‐like cell population in hepatocellular carcinoma (HCC) and served as a therapeutic target of acyclic retinoid (ACR), an orally administered vitamin A derivative that has demonstrated promising efficacy and safety in reducing HCC recurrence. This study investigated the role of MYCN as a predictive biomarker for therapeutic response to ACR and prognosis of HCC. MYCN gene expression in HCC was analyzed in the Cancer Genome Atlas and a Taiwanese cohort ( N = 118). Serum MYCN protein levels were assessed in healthy controls ( N = 15), patients with HCC ( N = 116), pre‐ and post‐surgical patients with HCC ( N = 20), and a subset of patients from a phase 3 clinical trial of ACR ( N = 68, NCT01640808). The results showed increased MYCN gene expression in HCC tumors, which positively correlated with HCC recurrence in non‐cirrhotic or single‐tumor patients. Serum MYCN protein levels were higher in patients with HCC, decreased after surgical resection of HCC, and were associated with liver functional reserve and fibrosis markers, as well as long‐term HCC prognosis (>4 years). Subgroup analysis of a phase 3 clinical trial of ACR identified serum MYCN as the risk factor most strongly associated with HCC recurrence. Patients with HCC with higher serum MYCN levels after a 4‐week treatment of ACR exhibited a significantly higher risk of recurrence (hazard ratio 3.27; p = .022). In conclusion, serum MYCN holds promise for biomarker‐based precision medicine for the prevention of HCC, long‐term prognosis of early‐stage HCC, and identification of high‐response subgroups for ACR‐based treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
- Liver Cancer Prevention Research Unit, RIKEN Cluster for Pioneering Research, Saitama, Japan.
- Department of Gastroenterology, Graduate School of Medicine, Gifu University, Gifu, Japan.
- Department of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
- Department of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
ORCID-Profile: Xian-Yang Qin, Shiou-Hwei Yeh, Feifei Wei, Luc Gailhouste, Ryosuke Tateishi, Hideo Baba, Kouichi Miura, Sae Ochi, Pei-Jer Chen
Förderung
- The Cell Science Research Foundation
- The Jikei University
- Tokyo Biochemical Research Foundation
- Japan Society for the Promotion of Science
- RIKEN
- Japan Agency for Medical Research and Development
- Taiwan Ministry of Education (MOE)
Zitieren
APA
Qin, X. Y., Shirakami, Y., Honda, M., Yeh, S. H., Numata, K., Lai, Y. Y., Li, C. L., Wei, F., Xu, Y., Imai, K., Takai, K., Chuma, M., Komatsu, N., Furutani, Y., Gailhouste, L., Aikata, H., Chayama, K., Enomoto, M., Tateishi, R., …, & Suzuki, H. (2024). Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. International Journal of Cancer. https://doi.org/10.1002/ijc.34893
Vancouver
Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, et al. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. International Journal of Cancer. 2024. doi:10.1002/ijc.34893
BibTeX
@article{Qin2024,
author = {Qin, Xian-Yang and Shirakami, Yohei and Honda, Masao and Yeh, Shiou-Hwei and Numata, Kazushi and Lai, Ya-Yun and Li, Chiao-Ling and Wei, Feifei and Xu, Yali and Imai, Kenji and Takai, Koji and Chuma, Makoto and Komatsu, Nagisa and Furutani, Yutaka and Gailhouste, Luc and Aikata, Hiroshi and Chayama, Kazuaki and Enomoto, Masaru and Tateishi, Ryosuke and Kawaguchi, Kazunori and Yamashita, Tatsuya and Kaneko, Shuichi and Nagaoka, Katsuya and Tanaka, Motohiko and Sasaki, Yutaka and Tanaka, Yasuhito and Baba, Hideo and Miura, Kouichi and Ochi, Sae and Masaki, Takahiro and Kojima, Soichi and Matsuura, Tomokazu and Shimizu, Masahito and Chen, Pei-Jer and Moriwaki, Hisataka and Suzuki, Harukazu},
title = {Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34893}
}
EUVIMED